Psoriatic arthritis (PsA) is a chronic, progressive disease that, untreated, may be associated with permanent joint damage, disability, impaired quality of life, and cardiovascular disease. Globally, it affects 0.1-1% of people, it is a common comorbidity of patients with psoriasis, affecting up to a quarter of those with moderate-to-severe disease. affecting them in a quarter percent of the U.S. population. PsA is an immune-mediated disease characterized by inflammation of the skin and nails disease or a family history of psoriasis in association with pluralistic musculoskeletal disease that may involve entheses, the spine, and peripheral joints. Unlike the clinical manifestations of inflammatory, pathophysiological processes of psoriasis, a failure to intervene early in PsA with treatment often results in damage that is irreversible. In all, patients with PsA incur about four times the direct medical costs as compared to the average medical patient.
This accredited educational activity identifies the critical components of the management process and offer solutions to close gaps in diagnosis and care, with the ultimate goals being the improvement of psoriatic arthritis management, treatment adherence, and health and cost outcomes.
The following HCPs: rheumatologists, dermatologists, and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in rheumatology and immunology; and any other HCPs with an interest in or who clinically encounter patients with PsA.
This program is supported by an educational grant from Mylan Inc., a Viatris Company.
This activity is free of charge.
Release Date: May 15, 2022 -- Expiration Date: May 15, 2024
Faculty: Peng Fan, MD
Faculty introduction, |
Introduction content: cursory refresher and review of PsA Epidemiology: statistics by severity Pathophysiology Clinical presentation; disease progression; complications, comorbidities, and burden of disease Evaluation, diagnosis, and associated pitfalls |
Treatment of PsA Peripheral arthritis vs. axial disease Prognosis Moderate-to-severe disease treatment cDMARDs: methotrexate, leflunomide, and phosphodiesterase-4 inhibition Adverse prognosis and resistance to cDMARDs Tumor necrosis factor-targeting therapy IL-17, -12, and -23-targeting therapies Selective T-cell costimulation Janus kinase inhibition Later-line agents Monitoring Recent clinical trial evidence and guideline updates Emerging and future therapies Disease flares and adverse events Patient case(s) |
Summary, conclusions, and best practice recap |
By the end of the session the participant will be able to:
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, CEO of ScientiaCME, has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by an educational grant from Mylan Inc., a Viatris Company.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.